Which version of the Pill is Cadence OTC seeking to take over-the-counter?

Cadence OTC owns the exclusive rights to Lo/Ovral and Alesse. Both of these products are oral contraceptive tablets that contain estrogen and progesterone. Millions of women have safely used both products for more than 2 decades. When approved by the FDA, they can be bought without a doctor’s prescription.

What is the difference between Lo/Ovral and Alesse?

Both products contain the same active ingredients at slightly different doses. Both options safely and effectively prevent pregnancy when used as directed.

Is the Pill available over-the-counter today?

Not in the US – not yet. Cadence OTC is the first health care company seeking to obtain OTC status for a combined oral contraceptive in the US.

Why should the Pill be available over-the-counter?

Many women who see their doctors regularly would still benefit from the convenience of OTC access for refills or lost Pills. Also, having a regular insurance or a health care provider is not an option for many women. It is important that women have access to safe and effective oral contraceptives whether or not they have a regular health care provider.

Millions of women do not have continuous health insurance or a regular health care provider and face significant obstacles getting access to the Pill. An OTC Pill will add an option for women who face these obstacles. It will create a level playing field for women who do not have health insurance or contraceptive coverage in their health insurance plans.

Why is the Pill not available over-the-counter?

The U.S. Food and Drug Administration (FDA) decides whether any product, including contraceptives, can be made available without a prescription. Before Cadence OTC, no other pharmaceutical company had applied to switch the birth control pill to OTC status.

Is it safe for a woman to take the birth control Pill?

The Pill has been used safely by more than 20 million women in the US over decades. It is safe for most women.


  • Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study
  • Oral contraceptive use and cancer: final report from the Oxford–Family Planning Association contraceptive study
  • Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer
  • Oral contraceptive use and risk of breast cancer: A meta-analysis of prospective cohort studies
  • Unintended Pregnancy in the United States
  • Hormonal Contraception
  • Should Oral Contraceptives Be Available without Prescription
  • Past oral contraceptive use and self-reported high blood pressure in postmenopausal women
  • An overview of oral contraceptives
  • Thrombotic risks of oral contraceptives
  • States Lead Effort to Let Pharmacists Prescribe Birth Control
  • Accuracy of Self-Screening for Contraindications to Combined Oral Contraceptive Use
  • Interest in over-the-counter access to oral contraceptives among women in the United States
  • A Survey of Teenagers’ Attitudes Toward Moving Oral Contraceptives
  • Over-the-Counter Access to Oral Contraceptives
  • Over-the-Counter Oral Contraceptives
  • D-75.995 Over-the-Counter Access to Oral Contraceptives
  • Changing Oral Contraceptives from Prescription to Over-the-Counter Status: An Opinion Statement of the Women’s Health Practice and Research Network of the American College of Clinical Pharmacy
  • Maternal use of oral contraceptives and risk of birth defects in Denmark: prospective, nationwide cohort study
  • Unintended Pregnancy in the United States